211245-64-6 Usage
General Description
4-(cyclopentylamino)-2-(methylthio)pyrimidine-5-carbaldehyde is a chemical compound with the molecular formula C11H14N4OS. It contains a pyrimidine ring with a cyclopentylamino group at the 4-position and a methylthio group at the 2-position, as well as a carbaldehyde group at the 5-position. 4-(cyclopentylaMino)-2-(Methylthio)pyriMidine-5-carbaldehyde is used in pharmaceutical and medicinal chemistry as a building block for the synthesis of various biologically active compounds. Its structure and properties make it a valuable intermediate in the development of potential drugs for various therapeutic applications.
Check Digit Verification of cas no
The CAS Registry Mumber 211245-64-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,1,2,4 and 5 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 211245-64:
(8*2)+(7*1)+(6*1)+(5*2)+(4*4)+(3*5)+(2*6)+(1*4)=86
86 % 10 = 6
So 211245-64-6 is a valid CAS Registry Number.
211245-64-6Relevant articles and documents
HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
-
, (2021/01/23)
Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AS CDK INHIBITORS
-
, (2021/09/17)
The pyrido[2,3-d]pyrimidin-7(8H)-ones of Formula (1) and pharmaceutical compositions containing compounds of Formula (1) as CDK inhibitors are disclosed herein. Methods and use of a compound of Formula 1 in the treatment of cancer and manufacture are also disclosed.
CYCLIN DEPENDENT KINASE INHIBITORS AND METHODS OF USE
-
, (2016/02/29)
The presently disclosed subject matter relates to methods and compositions for protecting healthy cells from damage due to DNA damaging agents. In particular, the presently disclosed subject matter relates to the protective action of selective cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to or that are at risk of exposure to DNA damage.
